BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Szczepanik A, Choi D, Brady B, Chandran MM, Diamond A, Do V, Fredrick S, Kaiser T, Khalil K, Laub MR, Leino A, Park JM, Pierce D, Rendulic T, Wiegel JJ, Fose J, Jorgenson MR. The use of non-transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician. Clin Transplant 2022;:e14743. [PMID: 35690919 DOI: 10.1111/ctr.14743] [Reference Citation Analysis]
2 Anderson PO. Treating Psoriasis During Breastfeeding. Breastfeed Med 2022. [PMID: 35271347 DOI: 10.1089/bfm.2022.0033] [Reference Citation Analysis]
3 Seishima M, Fujii K, Mizutani Y. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments. Am J Clin Dermatol 2022. [PMID: 35704168 DOI: 10.1007/s40257-022-00698-9] [Reference Citation Analysis]
4 Szabo TM, Frigy A, Nagy EE. Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. Int J Mol Sci 2021;22:13053. [PMID: 34884857 DOI: 10.3390/ijms222313053] [Reference Citation Analysis]
5 Costache DO, Feroiu O, Ghilencea A, Georgescu M, Căruntu A, Căruntu C, Țiplica SG, Jinga M, Costache RS. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. Int J Mol Sci 2022;23:5198. [PMID: 35563587 DOI: 10.3390/ijms23095198] [Reference Citation Analysis]
6 Han JH, Park HE, Kim YH, Jung JH, Lee JH, Park YM, Bang CH. Comparison of the risk of heart failure in psoriasis patients using anti-TNF α inhibitors and ustekinumab. ESC Heart Fail 2022. [PMID: 35174665 DOI: 10.1002/ehf2.13855] [Reference Citation Analysis]
7 Trovato E, Rubegni P, Prignano F. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opin Biol Ther 2022;:1-6. [PMID: 35726639 DOI: 10.1080/14712598.2022.2093106] [Reference Citation Analysis]
8 Gisondi P, Geat D, Maurelli M, Degli Esposti L, Bellinato F, Girolomoni G. Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines 2022;10:646. [DOI: 10.3390/vaccines10050646] [Reference Citation Analysis]
9 Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, Bardazzi F, Bernardini N, Bonamonte D, Bongiorno MR, Buligan C, Cusano F, Del Giudice MBF, Hachem ME, Fargnoli MC, Gualdi G, Guarneri C, Hansel K, Malara G, Mazzatenta C, Micali G, Narcisi A, Neri I, Oranges T, Panzone M, Parodi A, Restano L, Simonetti O, Venturini M, Di Lernia V. Update on the Management of Pediatric Psoriasis: An Italian Consensus. Dermatol Ther (Heidelb) 2022. [PMID: 35776408 DOI: 10.1007/s13555-022-00758-2] [Reference Citation Analysis]
10 Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, Guarneri C. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 2022;10:228. [DOI: 10.3390/biomedicines10020228] [Reference Citation Analysis]
11 Romozzi M, Bellavia S, Caldarola G, De Simone C, Luigetti M, Calabresi P, Di Filippo M, Masullo C, Lucchini M. Ixekizumab exposure associated with myelitis: A case report and a literature review. J Neuroimmunol 2021;361:577726. [PMID: 34628135 DOI: 10.1016/j.jneuroim.2021.577726] [Reference Citation Analysis]
12 Seyedmirzaei H, Rezaei N. Cytokine alterations in psoriasis: an updated review. Expert Rev Clin Immunol 2021;17:1323-35. [PMID: 34845948 DOI: 10.1080/1744666X.2022.2011720] [Reference Citation Analysis]